Spectral speech features may serve as noninvasive biomarkers for monitoring attention and executive function in major depressive disorder.

The top 5 most-read articles on major depressive disorder (MDD) in 2022 discussed US treatment updates, drug assistance in talk therapy, further exploration of transcranial magnetic stimulation’s ...

Major depressive disorder (MDD) is a debilitating psychiatric condition characterized by a persistently low mood, a lack of ...

Remission (MADRS total score ≤10) was seen in 65% of patients treated with lumateperone in combination with an oral antidepressant, at 6 months. The Food and Drug Administration (FDA) has approved ...

Please provide your email address to receive an email when new articles are posted on . The esketamine group had significantly improved C-SSRS and MADRS scores compared with those receiving midazolam.

Johnson & Johnson’s decision to splash out $14.6 billion on its purchase of Intra-Cellular Therapies earlier this year was largely driven by the acquired company's rising antipsychotic star Caplyta ...

Although antidepressants are a mainstay of MDD treatment, they are plagued by poor efficacy, high rates of relapse, and intolerable side effects. 40,41 Second-generation antidepressants, including ...

The approval of medicines called second-generation antipsychotics has allowed major depressive disorder (MDD) and other conditions linked to it to be treated. A person with MDD is usually prescribed ...

Objective To estimate the efficacy of exercise on depressive symptoms compared with non-active control groups and to determine the moderating effects of exercise on depression and the presence of ...

Depression and seasonal affective disorder (SAD) share similar symptoms, but depression can occur at any time of the year, while SAD follows a recurring seasonal pattern. For a SAD diagnosis, a person ...